title: Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
abstract: OBJECTIVE
  Type I epithelial ovarian cancers (EOCs) are reported to be relatively chemoresistant. This study sought to compare pretreatment chemoresponse assays in Type I vs. Type II EOCs.
  
  
  METHODS
  383 women with stage III-IV EOC enrolled in an observational study, with known chemoresponse assay results for 7 common therapeutic agents, were included. Type I EOCs were defined as grade 1 serous/endometrioid cancers and all clear cell/mucinous cancers. Type II EOCs were classified as grade 2-3 serous/endometrioid cancers and undifferentiated cancers. Chemotherapy assay responses were classified as sensitive (S), intermediately sensitive (I), or resistant (R). All patients were treated with platinum/taxane therapy following cytoreductive surgery.
  
  
  RESULTS
  Thirty (7.8%) tumors were classified as Type I EOC, and 353 (92.2%) as Type II EOC. Type I patients were younger at the time of diagnosis (median age: 57 vs. 62 years, p=0.018) and had longer survival compared to Type II patients (mPFS: 25.8 vs. 16.4 months, HR=1.71, p=0.042). Eighty-six percent of Type I EOC specimens demonstrated a sensitive chemoresponse assay result to at least 1 agent; 35.7% were pan-S to all 7 agents. After adjusting for stage, debulking status, and type of EOC, multi-drug resistance was twice as likely in women with Type I EOC compared to Type II EOC (pan-R, 14.3% vs. 6.8% (p=0.268); pan-S, 35.7% vs. 51.2% (p=0.183)), but did not attain statistical significance.
  
  
  CONCLUSIONS
  The majority of women with Type I EOC displayed assay sensitivity to at least one agent. Given the small sample size these findings need to be evaluated further.
authors.affiliation: Gynecologic Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Previs
authors.affiliation: Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Charles A
authors.initials: CA
authors.lastname: Leath
authors.affiliation: Gynecologic Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
authors.affiliation: Gynecologic Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Herzog
authors.affiliation: Gynecologic Oncology, Western Pennsylvania Hospital, Pittsburgh, PA, USA.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Krivak
authors.affiliation: Product Development, Helomics Corporation, Pittsburgh, PA, USA.
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Brower
authors.affiliation: Product Development, Helomics Corporation, Pittsburgh, PA, USA.
authors.forename: Chunqiao
authors.initials: C
authors.lastname: Tian
authors.affiliation: Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
authors.forename: Angeles Alvarez
authors.initials: AA
authors.lastname: Secord
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D055815:Young Adult
keywords: Chemoresponse assay; Clinical outcomes; Type I ovarian cancer